Human Embryonic-like ECM (hECM) Stimulates Proliferation and Differentiation in Stem Cells While Killing Cancer Cells

Area of Science:

• Biomaterials Science
• Developmental Biology
• Oncology

Background:

• Fetal development exhibits unique processes like scarless healing and tumor resistance.
• Embryonic extracellular matrix (ECM) can reprogram cancer cells.
• Human ECM (hECM) with embryonic characteristics is a novel therapeutic target.

Purpose of the Study:

• To develop and characterize a human ECM (hECM) with embryonic-like properties.
• To investigate the anti-cancer effects of hECM in vitro and in vivo.
• To explore therapeutic applications of hECM in cancer treatment.

Main Methods:

• Neonatal fibroblasts cultured in microcarrier suspension under hypoxia to secrete hECM.
• Characterization of hECM composition, including laminins, Collagen 4, and stem cell niche factors.
• In vitro and in vivo studies using various cancer cell lines (melanoma, adenocarcinoma, colon cancer, glioma) and animal models (tumcam, xenografts).

Main Results:

• hECM supports proliferation of human embryonic stem cells (hESCs) and mesenchymal stem cells (MSCs).
• Significant tumor growth inhibition (70-90%) observed in multiple cancer models.
• hECM selectively induces apoptosis in cancer cells and cancer stem cells via Caspase 9 upregulation.

Conclusions:

• hECM demonstrates potent anti-cancer properties.
• Potential therapeutic applications include biopsy needle coatings, post-tumor removal fillers, and direct tumor injectables.
• hECM represents a promising new avenue for cancer therapy.